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Background: Pedometer-based programs have elicited increased walking behaviors associated with improvements
in blood pressure in sedentary/low active postmenopausal women, a population at increased risk of cardiovascular
disease. Such programs typically encourage increasing the volume of physical activity with little regard for its
intensity. Recent advances in commercially available pedometer technology now permit tracking of both steps/day
and time in moderate (or greater) intensity physical activity on a daily basis. It is not known whether the dual
message to increase steps/day while also increasing time spent at higher intensity walking will elicit additional
improvements in blood pressure relative to a message to only focus on increasing steps/day. The purpose of this
paper is to present the rationale, study design, and protocols employed in WalkMore, a 3-arm 3-month blinded and
randomized controlled trial (RCT) designed to compare the effects of two community pedometer-based walking
interventions (reflecting these separate and combined messages) relative to a control group on blood pressure in
sedentary/low active post-menopausal women, a population at increased risk of cardiovascular disease.
Methods/Design: 120 sedentary/low active post-menopausal women (45-74 years of age) will be randomly assigned
(computer-generated) to 1 of 3 groups: A) 10,000 steps/day (with no guidance on walking intensity/speed/cadence;
BASIC intervention, n = 50); B) 10,000 steps/day and at least 30 minutes in moderate intensity (i.e., a cadence of at least
100 steps/min; ENHANCED intervention, n = 50); or a Control group (n = 20). An important strength of the study is the
strict control and quantification of the pedometer-based physical activity interventions. The primary outcome is systolic
blood pressure. Secondary outcomes include diastolic blood pressure, anthropometric measurements, fasting blood
glucose and insulin, flow mediated dilation, gait speed, and accelerometer-determined physical activity and sedentary
behavior.
Discussion: This study can make important contributions to our understanding of the relative benefits that walking
volume and/or intensity may have on blood pressure in a population at risk of cardiovascular disease.
Trial registration: ClinicalTrials.gov Record NCT01519583, January 18, 2012
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Cardiovascular disease remains the leading cause of
death in the U.S. [1]. and high blood pressure (hyperten-
sion) is one of the most common risk factors for both
cardiovascular disease and stroke [2]. The prevalence of
hypertension is positively associated with age [3], and is
higher among men than women at younger ages, but
these gender differences are reversed in older age [4]. At
least part of the rise in blood pressure observed in later
adulthood in women is related to menopause [5]. In-
creases in body mass index (BMI) account for some, but
not all, of the observed increases in hypertension preva-
lence in adults; and thus an increasingly sedentary life-
style has also been suggested as a contributory factor [6].
Based on objectively monitored behavior, less than 5% of
the adult population obtains commonly recommended
amounts (i.e., 30 minutes/day) of moderate-to-vigorous
physical activity, with the lowest prevalence observed in
women over 50 years old [7]. Even when intensity of
activity is not considered, it is apparent that post-
menopausal women are not very active. As a single illus-
trative example, traditional Amish women take 14,000
steps/day [8] whereas recent estimates indicate typical
American women over 50 years of age take less than
5,000 steps/day [9-11]. Being female, older, and having a
higher BMI were among the predictors of being classified
as sedentary (i.e., taking less that 5,000 steps/day) based
on objectively monitored data from the National Health
and Nutrition Examination Survey (NHANES) [12].
Taking less than 7,500 steps/day is indicative of physical
inactivity (i.e., not meeting public health recommen-
dations for accumulating moderate or greater physical
activity) [13] or otherwise being classified as “sedentary/
low active ” [14].
Meta-analyses of walking exercise programs (i.e., focused
on structured walking), [15,16] but also pedometer-based
programs [17] (i.e., focused on lifestyle walking) reduce
blood pressure. Studies of pedometer-based programs
employing a step goal [17], and in particular a 10,000
steps/day goal [18], appear to have had the greatest im-
pact on increasing physical activity. Attainment of this
level is considered consistent with the physical activity
levels of active individuals [14,19]. Moreau et al. [20]
showed that increasing physical activity levels in hyper-
tensive postmenopausal women from a baseline value of
approximately 5,000 to 10,000 steps/day elicited a 6 mm
Hg decrease in systolic blood pressure at 12 weeks and a
further 5 mm Hg reduction at 24 weeks. Prudence dic-
tates that any pedometer-determined steps/day goal be
congruent with existing public health guidelines. Consist-
ent evidence indicates that 30 minutes of at least moder-
ate intensity physical activity is equivalent to 3,000-4,000
steps in adults [21,22]. Further, there is consistent sup-
port for a stepping rate (i.e., cadence) of 100 steps/minuteto represent the lower bound of moderate intensity walk-
ing in adults [21,23-26], also producing 3,000 steps in
30 minutes (i.e., 100 steps/min * 30 minutes). To be con-
sidered a true translation of public health guidelines, at
least 3,000-4,000 steps of any goal expressed as a total
daily steps/day value should be of at least moderate in-
tensity (i.e., be ≥100 steps/minute) [27].
The purpose of this paper is to present the rationale,
study design, and protocols employed in WalkMore,
a randomized controlled trial (RCT) designed to com-
pare the impact of two pedometer-based walking inter-
ventions (BASIC vs. ENHANCED) relative to a control
group on blood pressure in sedentary/low active post-
menopausal women, a population at increased risk of car-
diovascular disease.
Methods/Design
Trial design
WalkMore is a 3-month long trial with outcome measures
at baseline and 3 months. The Principal Investigator and
assessment staff are blinded to participants’ randomized al-
location status. A biostatistician oversees the computer-
generated program that will be used to randomly assign
participants to 1 of 3 groups: A) 10,000 steps/day (with no
intervention on walking intensity/speed/cadence; BASIC
intervention, n = 50); B) 10,000 steps/day and at least
30 minutes in moderate intensity (i.e., at a cadence of at
least 100 steps/min; ENHANCED intervention, n = 50);
or a Control group (n = 20). The study was reviewed
and approved by the Pennington Biomedical Research
Center’s Institutional Review Board. The study is registered
at ClinicalTrials.gov (Record NCT01519583) and it will be
reported according to CONSORT guidelines [28].
Participants and recruitment
We will recruit 120 participants for the WalkMore
study. The Pennington Biomedical Research Center’s
Recruiting Core will manage all participant recruitment
activities (e.g., marketing, newspaper, billboards, email
campaigns, health fairs, public speaking appearances,
etc.). Potential participants responding to recruitment
activities will be directed to a website and/or call center
that is operated by 4 full-time recruiters. The core uti-
lizes an electronic message tracking application that
tracks webscreener and phone call activity, including a
“smart” electronic web and phone screen system that
facilitates screening potential participants upon initial
contact and seamlessly matches them with an appropri-
ate study, including WalkMore. A listserv was devel-
oped to manage email campaigns targeting the 12,000
subscribers who have opted to be notified of new
studies via email. The core also has access to demo-
graphic information for approximately 25,000 partici-
pants who can be targeted for study recruitment, including
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ling techniques” that take advantage of current partici-
pants’ social networks will be included as the study is
deployed.
Screening and eligibility
We will employ an extensive screening process which
we have found promotes adherence and excludes po-
tential participants who cannot commit to the study.
Web-based or telephone screening (≈ 15 minutes) will
be used to identify potentially eligible participants based
on sex (women), age (45-74 years), post-menopausal sta-
tus (self-reporting at least 12 months since last menses),
mobility (self-reporting physically capable of exercise),
and performance of regular physical activity (yes/no).
Potential participants identified at this stage will be
invited to attend a 30-min group orientation session
(scheduled in the early evenings once or twice a week, as
numbers require) to learn more about the study, includ-
ing randomization procedures, study requirements, per-
sonal risks and benefits, and participant rights. Potential
participants who wish to continue with the screening
process will be scheduled for the first of three subsequent
screening visits and sent home with a copy of the study’s
informed consent form to read over before their first
screening visit.
Upon arrival at their first screening visit (SV1; ≈ 60 mi-
nutes), the study will be reviewed once more, all ques-
tions are answered, and participants will be asked to
provide written informed consent prior to the admin-
istration of any of the following study procedures. A
medical and health history will be obtained. Inclusion/
exclusion criteria are summarized in Table 1. Participants
reporting significant cardiovascular disease/disorders
(including diabetes) or other significant medical condi-
tions considered life-threatening or potentially interfering
with or being aggravated by exercise, recently (with pre-
vious 6 weeks) donating blood or losing ≥20 kg in the
previous year, having been hospitalized for mental illness
within the previous 5 years, or planning to be out of the
area for more than 3 weeks over the next 3 months will
be excluded. Participants are further queried about their
exercise habits to confirm eligibility (continues to self-
report as not a regular exerciser). Blood pressure is taken
and those with systolic pressure values of 130-179 mmHg
or diastolic pressure values of 85-99 mmHg will be
included. Participants taking blood pressure lowering
medication and meeting the above criteria will still be
eligible. Height, weight, and waist circumference are
obtained; those with a BMI between 25-45 kg/m2 are in-
cluded. Participants are then asked to wear a pedometer
(NL-1000, NewLifestyles) and record their daily steps for
one week before returning for their second screening visit
(SV2).At SV2 (≈ 20 minutes), participants’ written records of
their daily steps will be reviewed and compared to those
recorded by the pedometer’s internal memory (not previ-
ously disclosed to participants). Those participants who
wear the pedometer for at least 4 days and average < 7500
steps/day (defined as sedentary or low active [14]) will be
asked to wear an accelerometer (GT3X+, ActiGraph LLC,
Pensacola, FL) for one week before returning for their third
and final screening visit (SV3, ≈ 30 minutes). At SV3,
the participant’s accelerometer will be downloaded and
reviewed for evidence of wearing compliance. Participants
who wear the accelerometer for at least 4 days (≥ 10 hours
each day), are willing to accept randomized group assign-
ment, and remain committed to working through potential
scheduling conflicts and other logistical issues that may
come up during the intervention will be enrolled in the
study and subsequently scheduled for baseline measures
and randomization procedures. Participant’s accelerometer
data collected during their screening process will serve as
their baseline physical activity and sedentary behavior data.
Outcome measurements
Primary and secondary outcomes
The primary outcome is systolic blood pressure assessed
using American Heart Association (AHA) guidelines
[30]. Secondary outcomes include diastolic blood pres-
sure [30], anthropometric measurements [29] (height,
weight, waist circumference), fasting blood glucose and
insulin, flow mediated dilation (FMD) [31], gait speed
(assessed using a 16-foot GAITRite computerized walk-
way system, CIR Systems, Havertown, PA, USA), and
accelerometer-determined physical activity and seden-
tary behavior. Additional protocol details for flow medi-
ated dilation, gait speed, and accelerometry follow.
Flow mediated dilation (FMD)
FMD will be used to determine endothelium-dependent
dilation of the brachial artery. All FMD measurements
will occur in the morning at approximately the same
time of day at pre-intervention and post-intervention.
Upon arrival to the research center, participants will rest
quietly for 15 minutes supine in a hospital bed in a
temperature controlled room. Brachial artery assess-
ments will be obtained using 2D and Doppler ultrasound
measurements, placed over the brachial artery in the
elbow area on the non-dominant arm, with a 7.5 MHz lin-
ear array transducer and the brachial artery mean blood
velocity will be measured using a pulse-wave Doppler
with on-line angle correction and analysis software.
When an optimal view of the brachial artery is obtained
where the anterior and posterior borders of the endothe-
lium are clearly visible, baseline images (each during a
different cardiac cycle) will be taken to determine resting
brachial diameter. Following completion of all baseline
Table 1 Inclusion/exclusion criteria for women participating in WalkMore
Inclusion criteria
Age 45-74 years
Post-menopausal status Self-reporting at least 12 months since last menses
Mobility Reporting physically capable of exercise (yes/no)
Physically inactive Self-reported exercise behavior (yes/no)
Objectively determined sedentary Average ≤5,000 steps/day during screening
Overweight/obese Objectively verified BMI 25 – 45 kg/m2 OR waist circumference >88 cm [29]
Informed consent The capability and willingness to give written informed consent, to understand exclusion
criteria, and to accept the randomized group assignment are required.
Blood pressure Systolic values of 130-179 mmHg or diastolic pressure values of 85-99 mmHg. Participants
taking blood pressure lowering medication and meeting the above criteria are still eligible.
Exclusion criteria
Significant cardiovascular disease or disorders Including but not limited to arrhythmias, myocarditis, cardiomyopathy, congestive heart
failure, stroke or transient ischemic cerebral attacks, peripheral vascular disease with
intermittent claudication, acute, chronic or recurrent thrombophlebitis
Other significant medical conditions Including but not limited to diabetes, chronic or recurrent respiratory, gastrointestinal,
neuromuscular, neurological, or psychiatric conditions. Musculoskeletal problems interfering
with exercise. Immunodeficiency diseases or a positive HIV test. Malignancies in the past
5 years, with the exception of skin cancer therapeutically controlled. Any other medical
condition or disease that is life-threatening or that can interfere with or be aggravated
by exercise
Recent blood donation Blood donation during the 6 weeks before the baseline evaluation (participants also will
be asked to refrain from blood donation during study)
Large weight loss 20 or more kilograms in the past year
Other exclusions Hospitalization for mental illness within the past 5 years.Plans to be out of the city more
than 3 weeks over the next 3 months.
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200 mmHg using a rapid inflation/deflation pneumatic
cuff around the forearm, and held for 5 minutes in order
to occlude the brachial artery. After this period of ische-
mia, the blood pressure cuff will be rapidly deflated, and
images of the brachial artery diameter and blood flow
velocity measurements will occur approximately every
5 seconds for 2 minutes. All brachial artery images
are analyzed using a custom designed edge-detection and
wall tracking software (Brachial Analyzer, Medical Imaging
Applications, Iowa City, Iowa.).
Gait speed
Gait variables (e.g., speed, cadence) will be assessed using
the GAITRite computerized walkway system. Participants
will be given a 2-meter acceleration and deceleration zone
on either end of the walkway and two practice trials before
performing the tested conditions. Participants will then be
asked to perform two crossings at six self-selected walking
speeds: very slow, slow, preferred/normal, fast, very fast,
and as-fast-as-you-can (without running). The first set of
crossings will always be at the preferred/normal speed. The
remaining sets will be counter-balanced between those that
are progressively faster than preferred/normal and those
that are progressively slower. Rest will be provided asnecessary. Outputs will be averaged for the two crossings
within each speed set.
Accelerometry
The selected accelerometer, the ActiGraph GT3X+, is the
most widely used accelerometer in ambulatory monitoring
research and will be used in WalkMore to detect minute-
by-minute physical activity and sedentary behavior using
previously validated cut points [32,33]. A cut point is an
activity count value that corresponds to a designated inten-
sity level (e.g., light, moderate, and vigorous intensity). This
accelerometer has been validated as an accurate measure
of frequency, intensity and duration of physical activity
[32,34]. More recently it has been used to estimate time in
sedentary behaviors [33] and it is also possible to examine
patterns of transitions between behaviors (e.g., from seden-
tary to higher intensity activities) [35]. It also provides an
independent (i.e., distinct form pedometer data collected
during the intervention, see below) estimate of steps/day
and cadence (steps/min) [10,36].
Interventions
Common program elements
Both pedometer-based physical activity interventions im-
plemented in WalkMore will be modeled off the success
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regardless of intervention group assignment, participants
monitor their own daily community-based walking using
pedometers and attend weekly meetings to review the
previous week’s walking behaviours, discuss preferred
strategies for success, and recommit to goals. The meet-
ings with the interventionist will primarily be group-
based, but accommodations will be made for individual
meetings as necessary. Participants will be given pe-
dometers and instructions focused on goal-setting and
problem-solving, as well as calendars for self-monitoring
and recording steps/day. Each meeting (held in a non-
clinical setting) will also include a short walk (with op-
tions for being outside or inside, as weather permits).
Participants will be taught how to monitor their own be-
havior, compute their own average steps/day each week
(and time in moderate or greater intensity if this is their
particular group assignment, see below), and recognize
relapse (defined as not achieving their steps/day and/or
time in moderate or greater intensity activity on any
single week). Participants will also be encouraged to
develop and share (with interventionists and with peers in
their group meetings) their own strategies for achieving
their goals.
For intervention tracking purposes, we have selected
to use the NL-1000 distributed in the U.S. by New
Lifestyles, Inc. The NL-1000 is a piezoelectric pedometer
that is considered more accurate than the more com-
monly used Yamax pedometer in detecting steps/day in
obese individuals [38] who we anticipate will form a large
proportion of recruited participants. Further it has an
on-board 7-day memory, allowing us to verify participant
records for the same time period.
BASIC vs. ENHANCED Interventions
Participants assigned to the BASIC intervention (10,000
steps/day with no guidance with regards to walking in-
tensity/speed/cadence) may accumulate their daily steps
in any manner they prefer (e.g., attending a mall walking
program, walking children to school, walking at work,
walking for errands, etc.). There will be absolutely no
emphasis on intensity of walking. They will track their
behavior using the NL-1000 but will never be shown the
function that allows tracking of time in moderate or
greater intensity activity.
Participants in the ENHANCED intervention will also
be instructed to take 10,000 steps/day, but in addition
will be encouraged to take make at least 3,000-4,000 of
these steps at moderate or greater intensity (i.e., at a ca-
dence of at least 100 steps/min) in order to achieve a
daily goal of 30 minutes in moderate or greater intensity.
They will track their behavior, both steps/day and time
in moderate or greater intensity, using the NL-1000. We
plan to verify records for the previous 7 days each timeparticipants in the two intervention groups meet with
the interventionist.
Control group
Participants allocated to the control group will be asked
to continue living their lifestyle as usual and to report
back for a final assessment at 3 months.
Adherence plan
We are defining acceptable adherence to the study
protocol as averaging their goal steps/day (and/or time
in moderate or greater intensity) at least 5 days/week
and 83% of the weeks on study. The process of averaging
steps/day over a week allows flexibility in being able to
make up for lower days by having higher days. Further,
participants will be excused from meeting their assigned
steps/day goal up to 2 weeks during the 3-month long
trial. For example, an individual assigned to the 10,000
steps/day condition would be expected to average 10,000
steps/day for at least 10 weeks of the 12 weeks on trial
to be adherent. This provides time for vacations, illness,
and other family and work commitments.
Everyone, including participants allocated to the con-
trol condition, will receive a pedometer upon study com-
pletion. We will also provide a total incentive of up
to $100 US per individual as compensation for their time
participating in the study; participants often must take
off time to attend clinic assessments and this nominal
compensation is appropriate. The $100 incentive is not
awarded at one time but, is delivered as the participant
progresses through the study. All participants will be
able to earn this payment by adhering to study require-
ments, including meeting the 83% target adherence rate
in order to receive the entire $100. The participants will
receive $50 ($25 check per visit) for completion of both
the baseline (0 month) and the 3 month assessment visit.
From week 3 to week 12 of both walking interventions,
participants will receive an additional $5 for every week
they average at least 10,000 steps/day. Control partici-
pants will receive the additional $50 for remaining in the
study for its duration.
Statistical power and sample size
In the RCT conducted by Moreau et al. [20], mean resting
systolic blood pressure among postmenopausl women was
reduced by 6 mm Hg after a 12-week walking program.
Likewise, in the comparative-effectiveness trial conducted
by Seals et al. [39], mean resting systolic blood pressure
was reduced by 5 mm Hg in postmenopausal women after
a 13 week walking program. Based upon data presented by
Seals et al. [39], we estimated that the standard deviation
of systolic blood pressure change in WalkMore will be
6 mm Hg. Thus, a net of 42 completers per each interven-
tion group and 17 completers in the control group will be
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systolic blood pressure change for any comparison (Basic
vs. Enhanced, Basic vs. Control, and Enhanced vs. Control)
at 80% power while maintaining global α = 0.05 (0.05/3 =
0.01667 for each of the 3 possible comparisons). Assuming
a maximum attrition of 15%, 120 participants will be en-
rolled in the study. We will randomize 50 participants into
the BASIC group, 50 participants into the ENHANCED
group, and 20 participants into the Control group.
Statistical analysis
The primary analysis will be on changes in systolic blood
pressure at 12 weeks, comparing the 2 intervention groups
relative to the control condition. Summary statistics (mean,
standard deviations, ranges, medians, proportions) will
be calculated for systolic and diastolic blood pressures
and all other outcome variables of interest. Variables
will be log-transformed as needed, to better approximate
Gaussian distributions. Mixed effects statistical models will
be employed to analyze the fixed effects of interventions
and the random effects of subjects with respect to outcome
trajectories across time. Analysis of reduction in response
(e.g., blood pressure) will employ analysis of covariance to
account for baseline variability. We will use graphical tech-
niques (scatter and box-plots) to elicit associations and
trends in the data and to guide the development of appro-
priate models. Standard diagnostics (residuals, goodness-
of-fit tests) will assess model adequacy. All computations
will be conducted with the statistical software package SAS
version 9.3 (SAS Institute, Cary, NC).
Discussion
Capitalizing on the appeal of walking as a feasible behav-
ior for the vast majority of the population and the prac-
ticality of pedometer-based programming, WalkMore is
designed to evaluate the comparative effectiveness of
increasing ambulatory physical activity with and without
an emphasis on its intensity on blood pressure in seden-
tary postmenopausal women. This study will inform
public health and health promotion efforts to deliver clear
and actionable physical activity messages related to im-
proving blood pressure in a subpopulation at increased
risk of cardiovascular disease. This study will also yield
insights into the extent to which secondary outcomes are
affected by increased ambulatory physical activity with
and without an emphasis on its intensity.
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